INS and Hypoglycemia: The most recently marketed Degludec, which is a long-acting insulin analog with a prolonged half-life and ultra-flat kinetics [11], is the best choice in DM1 patients requiring lower HbA1c targets with the consequent potential higher risk of hypoglycemia [11, 17].